The opioid misuse epidemic is a serious public health crisis. Opioid-involved deaths continue to rise and the potency of illicitly manufactured synthetic opioids has increased, creating challenges for the healthcare system to provide multifaceted specialized care. Elements of the regulation around buprenorphine, 1 of 3 drugs approved to treat opioid use disorder (OUD), constrain treatment options for patients and providers alike. Updates to this regulatory framework, particularly around dosing and access to care, would enable providers to better treat the changing landscape of opioid misuse. Specific actions to this end are to: (1) Increase buprenorphine dosing flexibility based on FDA labeling which drives payor policies; (2) Restrict local government and institutional impositions of arbitrary access and dosing limits for buprenorphine; and (3) Liberalize buprenorphine initiation and maintenance via telemedicine for OUD.
SchollLSethPKariisaMWilsonNBaldwinG.Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR. 2018;67(5152):1419-1427.
3.
HanYYanWZhengYKhanMZYuanKLuL.The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. Transl Psychiatry. 2019;9(1-2):282.
4.
CiccaroneD.The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344-350.
5.
KlineAMatternDCoopermanN, et al. Opioid overdose in the age of fentanyl: risk factor differences among subpopulations of overdose survivors. Int J Drug Policy. 2021;90:103051.
6.
MaJBaoYPWangRJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019;24(12):1868-1883.
7.
BaserOChalkMFiellinDAGastfriendDR.Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235-S248.
ListerJJWeaverAEllisJDHimleJALedgerwoodDM.A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273-288.
11.
CantorJPowellDKofnerASteinBD.Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020. Drug Alcohol Depend. 2021;229(Pt A):109107.
12.
JoudreyPJBartGBroonerRK, et al. Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: a National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. Subst Abus. 2021;42(3):245-254. Erratum in: Subst Abus. 2022;43(1):691.
13.
GhoshSMKlaireSTanguayR, et al. A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings. Can J Addict. 2019;10(4):41-50.
14.
AhmedSBhivandkarSLonerganBBSuzukiJ.Microinduction of buprenorphine/naloxone: a review of the literature. Am J Addict, 2021;30:305-315.
15.
SaalDLeeF.Rapid induction therapy for opioid-use disorder using buprenorphine transdermal patch: a case series. Perm J. 2020;24(19):124
CraneKSneadJStanleyRAveryJGhoshSMMintsG.Intravenous buprenorphine micro-dosing induction in a patient on methadone treatment: a case report. J Acad Consult Liaison Psychiatry. 2021;62(2):243-247.
18.
HerringAAVosooghiAALuftigJ, et al. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Netw Open. 2021;4(7):e2117128.
American College of Emergency Physicians. Buprenorphine use in the emergency department tool. 2018. Accessed on November 15, 2022. https://www.acep.org/patient-care/bupe/
21.
ChambersJKimDPopeEGraffJWilkinsonCNeumannP.Specialty drug coverage varies across commercial health plans in the US. Health Affairs. 2018;37(7):1041-1047.
22.
ZubietaJKGreenwaldMLombardiU, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacol. 2000;23:326-334.
23.
LarochelleMBernsonDLandT, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. A cohort study. Ann Int Med. 2018;169(3):137-145.
24.
HserYISaxonAHuangD, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1-2):79-87.
25.
PizzicatoLNHomJKSunMJohnsonCCVinerKM.Adherence to buprenorphine: an analysis of prescription drug monitoring program data. Drug Alcohol Depend. 2020;216:108317.
26.
FareedAVayalapalliSCasarellaJDrexlerK.Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1-2):8-18.
27.
ShulmanMWeissRRotrosenJNovoPCostelloENunesEV.Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 “optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)”. Addict Sci Clin Pract. 2021;16(1-2):15. doi:10.1186/s13722-021-00223-z
28.
AhmadiJJahromiMSGhahremaniD, et al. Single high-dose buprenorphine for opioid craving during withdrawal. Trials. 2018;19:675.
29.
ShulmanMWaiJMNunesEV.Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567-580.
30.
InfantinoRMattiaCLocariniPPastoreALMaioneSLuongoL.Buprenorphine: far beyond the “ceiling”. Biomolecules. 2021;11(6):816.
31.
Lo ReMChaplinMAronowBModesto-LoweV.Buprenorphine overdose in young children: an underappreciated risk. Clin Pediatr. 2019;58(6):613-617.
32.
WightmanRSPerroneJScagosRKriegerMNelsonLSMarshallBDL. Opioid overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis. J Med Toxicol. 2021;17(1-2):10-15.
33.
BoasRAVilligerJW.Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57(2):192-6.
34.
BrandtCAtkinsonTJ.A review of the safety of buprenorphine in special populations. Am J Med Sci. 2022;364:675-684.
35.
GreenwaldMKJohansonCEMoodyDE, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000-2009.
36.
GreenwaldMKComerSDFiellinDA.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1-11.
37.
JonesHEJohnsonREJasinskiDR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79(1-2):1-10.
38.
WongJSaverBScanlanJM, et al. Does maternal buprenorphine dose affect severity or incidence of neonatal abstinence syndrome?J Addict Med. 2018;12(6):435-441.
MattickRPKimberJBreenCDavoliM.Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004;3:CD002207.
41.
ChilcoatHDAmickHRSherwoodMRDunnKE.Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148-157.
42.
LeeJDNunesEVJrNovoP, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318.
43.
Andraka-ChristouBRandall-KosichOGolanM, et al. A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. Health Justice. 2022;10(1-2):14.
44.
Andraka-ChristouBClarkMHAtkinsDNDel PozoB.Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder. Subst Abus. 2022;43(1-2):425-432.
45.
Andraka-ChristouBGolanOTotaramROhamaMSalonerBGordonAJSteinBD.Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. Ann Med. 2023;55(1-2):514-520.
46.
ChanBBougatsosCPriestKCMcCartyDGrusingSChouR.Opioid treatment programs, telemedicine and COVID-19: a scoping review. Subst Abus. 2022;43(1-2):539-546.
47.
BronsonJStroopJZimmerSBerzofskyM. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007–2009. Special report. Office of Justice Programs, Bureau of Justice Statistics, US Department of Justice. 2017. Accessed November 16, 2022. https://bjs.ojp.gov/content/pub/pdf/dudaspji0709.pdf
KrsakMMontagueBTTrowbridgePJohnsonSCBinswangerIA.Opioid use and chronic infections: the value of addressing the syndemic in correctional settings via telemedicine guidance and broader use of long-acting medications. J Infect Dis. 2020;222(Suppl 5):S486-S493. doi:10.1093/infdis/jiaa001
53.
LinLAFortneyJCBohnertASBCoughlinLNZhangLPietteJD.Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. J Subst Abuse Treat. 2022;133:108492.
54.
LinLAZhangLKimHMFrostMC.Impact of COVID-19 telehealth policy changes on buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2022;179(10):740-747.
RettigRYarmolinskyA, eds. Institute of medicine committee on federal regulation of methadone treatment. National Academies Press; 1995. Accessed February 21, 2023https://www.ncbi.nlm.nih.gov/books/NBK232114/
JonesCMComptonWMHanBBaldwinGVolkowND.Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiatry. 2022;79(9):932-934.
63.
FerrariACocciaCPBertoliniASternieriE.Methadone—metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9. doi:10.1016/j.phrs.2004.05.002
64.
DoernbergMKrawczykNAgusDFingerhoodM.Demystifying buprenorphine misuse: has fear of diversion gotten in the way of addressing the opioid crisis?Subst Abuse. 2019;40(2):148-153.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
